Chitosan as an adjuvant for a Helicobacter pylori therapeutic vaccine

Gong,Yanfeng; Tao,Liming; Wang,Fucai; Liu,Wei; Jing,Lei; Liu,Dongsheng; Hu,Sijun; Xie,Yong; Zhou,Nanjin

doi:10.3892/mmr.2015.3950

September-2015 Volume 12 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

September-2015 Volume 12 Issue 3

Full Size Image

Article Open Access

Chitosan as an adjuvant for a Helicobacter pylori therapeutic vaccine

Authors:
- Yanfeng Gong
- Liming Tao
- Fucai Wang
- Wei Liu
- Lei Jing
- Dongsheng Liu
- Sijun Hu
- Yong Xie
- Nanjin Zhou
View Affiliations / Copyright

Affiliations: Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330000, P.R. China, Department of Obstetrics, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330000, P.R. China, Department of Biochemistry and Molecular Biology, Jiangxi Medical Science Institute, Nanchang, Jiangxi 330006, P.R. China

Copyright: © Gong et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].
Pages: 4123-4132
|
Published online on: June 17, 2015

https://doi.org/10.3892/mmr.2015.3950
Expand metrics +

Abstract

The aim of the present study was to delineate the therapeutic effect of a Helicobacter pylori vaccine with chitosan as an adjuvant, as well as to identify the potential mechanism against H. pylori infection when compared with an H. pylori vaccine, with cholera toxin (CT) as an adjuvant. Mice were first infected with H. pylori and, following the establishment of an effective infection model, were vaccinated using an H. pylori protein vaccine with chitosan as an adjuvant. Levels of H. pylori colonization, H. pylori‑specific antibodies and cytokines were determined by enzyme‑linked immunosorbent assay. The TLR4 and Foxp3 mRNA and protein levels were determined by reverse transcription polymerase chain reaction and immunohistochemistry, respectively. It was identified that the H. pylori elimination rate of the therapeutic vaccine with chitosan as an adjuvant (58.33%) was greater than the therapeutic vaccine with CT as an adjuvant (45.45%). The therapeutic H. pylori vaccine with chitosan as an adjuvant induced significantly greater antibody and cytokine levels when compared with the control groups. Notably, the IL‑10 and IL‑4 levels in the groups with chitosan as an adjuvant to the H. pylori vaccine were significantly greater than those in the groups with CT as an adjuvant. The mRNA expression levels of TLR4 and Foxp3 were significantly elevated in the mice that were vaccinated with chitosan as an adjuvant to the H. pylori vaccine, particularly in mice where the H. pylori infection had been eradicated. The H. pylori vaccine with chitosan as an adjuvant effectively increased the H. pylori elimination rate, the humoral immune response and the Th1/Th2 cell immune reaction; in addition, the therapeutic H. pylori vaccine regulated the Th1 and Th2 response. The significantly increased TLR4 expression and decreased CD4+CD25+Foxp3+Treg cell number contributed to the immune clearance of the H. pylori infection. Thus, the present findings demonstrate that in mice the H. pylori vaccine with chitosan as an adjuvant exerts an equivalent immunotherapeutic effect on H. pylori infection when compared with the H. pylori vaccine with CT as an adjuvant.

View Figures

View References

1	Sijun H and Yong X: Helicobacter pylori vaccine: mucosal adjuvant & delivery systems. Indian J Med Res. 130:115–124. 2009.PubMed/NCBI
2	Barrette RW, Szczepanek SM, Rood D, et al: Use of inactivated Escherichia coli enterotoxins to enhance respiratory mucosal adjuvanticity during vaccination in swine. Clin Vaccine Immunol. 18:1996–1998. 2011. View Article : Google Scholar : PubMed/NCBI
3	Synowiecki J and Al-Khateeb NA: Production, properties, and some new applications of chitin and its derivatives. Crit Rev Food Sci Nutr. 43:145–171. 2003. View Article : Google Scholar : PubMed/NCBI
4	van der Lubben IM, Verhoef JC, Borchard G and Junginger HE: Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci. 14:201–207. 2001. View Article : Google Scholar : PubMed/NCBI
5	Li X, Min M, Du N, Gu Y, Hode T, Naylor M, Chen D, Nordquist RE and Chen WR: Chitin, chitosan, and glycated chitosan regulate immune responses: the novel adjuvants for cancer vaccine. Clin Dev Immunol. 2013:3870232013. View Article : Google Scholar : PubMed/NCBI
6	Kang ML, Kang SG, Jiang HL, et al: In vivo induction of mucosal immune responses by intranasal administration of chitosan microspheres containing Bordetella bronchiseptica DNT. Eur J Pharm Biopharm. 63:215–220. 2006. View Article : Google Scholar : PubMed/NCBI
7	Xie Y, Zhou NJ, Gong YF, et al: The immune response induced by H. pylori vaccine with chitosan as an adjuvant and its relation to immune protection. World J Gastroenterol. 13:1547–1553. 2007. View Article : Google Scholar : PubMed/NCBI
8	Gong YF, Xie Y, Zhou NJ, et al: Cellular immunity induced by H. pylori vaccine with chitosan as an adjuvant. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 23:595–599. 2007.In Chinese. PubMed/NCBI
9	Bacon A, Makin J, Sizer PJ, et al: Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun. 68:5764–5770. 2000. View Article : Google Scholar : PubMed/NCBI
10	Goto T, Nishizono A, Fujioka T, Ikewaki J, Mifune K and Nasu M: Local secretory immunoglobulin A and postimmunization gastritis correlate with protection against Helicobacter pylori infection after oral vaccination of mice. Infect Immun. 67:2531–2539. 1999.PubMed/NCBI
11	Lee CK, Weltzin R, Thomas WD Jr, et al: Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J Infect Dis. 172:161–172. 1995. View Article : Google Scholar : PubMed/NCBI
12	Saldinger PF, Porta N, Launois P, et al: Immunization of BALB/c mice with Helicobacter urease B induces a T helper 2 response absent in Helicobacter infection. Gastroenterology. 115:891–897. 1998. View Article : Google Scholar : PubMed/NCBI
13	Eisenberg JC, Czinn SJ, Garhart CA, et al: Protective efficacy of anti-Helicobacter pylori immunity following systemic immunization of neonatal mice. Infect Immun. 71:1820–1827. 2003. View Article : Google Scholar : PubMed/NCBI
14	Hori S, Nomura T and Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science. 299:1057–1061. 2003. View Article : Google Scholar : PubMed/NCBI
15	Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J and Palena C: IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood. 110:3192–3201. 2007. View Article : Google Scholar : PubMed/NCBI
16	Nair S, Boczkowski D, Fassnacht M, Pisetsky D and Gilboa E: Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res. 67:371–380. 2007. View Article : Google Scholar : PubMed/NCBI
17	Johnson BD, Jing W and Orentas RJ: CD25⁺ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma. J Immunother. 30:203–214. 2007. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Chitosan as an adjuvant for a Helicobacter pylori therapeutic vaccine

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Figure 8

Related Articles